Navigation Links
BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU
Date:8/17/2010

NOVATO, Calif., Aug. 17 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the first subject has initiated treatment in a Phase 3b study (PKU-016) to evaluate the effects of Kuvan (sapropterin dihydrochloride) on neuropsychiatric symptoms in subjects with phenylketonuria (PKU).  BioMarin expects to report results in the first half of 2012.

"We hope that this trial will provide quantitative data regarding the neuropsychiatric effects of Kuvan for PKU patients, and if successful, will continue to build its value proposition and to drive the continued expansion of the market," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin. "Although we have heard anecdotal accounts from patients and physicians regarding Kuvan's impact beyond blood Phe level reduction, BioMarin has never formally evaluated these endpoints in a company trial due to the extremely short development time for Kuvan.  We are excited to have this important study underway, and if the results are positive, we plan to file for a label amendment.  We also look forward to upcoming data from several investigator-sponsored studies on the neurocognitive effects of Kuvan at the SSIEM meeting in Istanbul in late August."

The Phase 3b study is a double-blind, placebo-controlled, randomized 28-week study (2-week screening period, 13-week randomized treatment period, 13-week open-label treatment period) to evaluate the safety and therapeutic effects of sapropterin dihydrochloride on neuropsychiatric symptoms in subjects with PKU.  The study will enroll approximately 200 subjects ages twelve and above at approximately 40 sites in the U.S. and Canada.  

The primary efficacy variable for symptoms of attention deficit hyperactivity disorder (ADHD) will be evaluated using the Attention-Deficit Hyperactivity Disorder Rating Scale (ASRS) in sub
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. BioMarin Announces FDA Approval for Kuvan
3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
8. BioMarin to Present at the Oppenheimer Healthcare Conference
9. BioMarin Announces Third Quarter 2009 Financial Results
10. BioMarin to Acquire LEAD Therapeutics
11. BioMarin to Present at the Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014 HeartWare ... leading innovator of less invasive, miniaturized circulatory support technologies ... today announced that it expects revenues for the fourth ... expected full-year 2013 revenues to approximately $208 million. ...
(Date:1/14/2014)... Jan. 14, 2014 InformEx, North America,s ... high-value chemistry, will hold the 30 th edition of ... Convention Center from January 21-24. (Logo: ... top pharmaceutical, fine chemical and specialty chemical companies will take ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... , one of the nation,s largest institutional pharmacy ... as its new senior vice president of sales ... position, Gauff will be responsible for leading a ... Remedi,s innovative offerings, including the continued roll-out of ...
... CareFusion today launched the Nicolet™ EEG (Electroencephalography) ... wave data used for the diagnosis and treatment ... http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO ) The Nicolet EEG ... into a single, portable unit for pediatrics and adults ...
Cached Medicine Technology:Remedi SeniorCare® Appoints Corey Gauff SVP of Sales and Account Management 2CareFusion Launches Wireless Diagnostic and Monitoring Neurological Device 2
(Date:7/9/2014)... July 10, 2014 For the first time, researchers ... Aboriginal population in Canada uses health care. A new ... to clearly demonstrate the unique challenges faced by urban ... St. Michael,s Hospital. , The findings, published today ... urban First Nations individuals and the general population. , ...
(Date:7/9/2014)... was told she had an aneurysm, she figured an invasive ... "I was devastated," said Wakulich, who is 56 years old ... a serious diagnosis. Then I met Dr. Bernard Bendok who ... invasive procedure. It was something I didn,t even know was ... U.S. clinical trial to evaluate the safety and effectiveness of ...
(Date:7/9/2014)... cancer, researchers have uncovered mutations in a cell-signaling pathway ... knowledge may expand treatments for patients because drugs targeting ... are in clinical trials. , Reporting July 9 in ... (TCGA), including researchers at Washington University School of Medicine ... studied tumors from 230 patients with lung adenocarcinoma. , ...
(Date:7/9/2014)... found that fecal transplantation is effective and safe for ... is the result of a study led by Colleen ... Gastrointestinal Medicine at The Women,s Medicine Collaborative. The study ... of print in the American Journal of Gastroenterology ... diff , has increased to epidemic proportions over the ...
(Date:7/9/2014)... are personal and subjective, the human brain turns ... emotions across different senses, situations and even people, ... Adam Anderson. , "We discovered that fine-grained patterns ... area of the brain associated with emotional processing, ... individual,s subjective feeling," says Anderson, associate professor of ...
Breaking Medicine News(10 mins):Health News:Urban Aboriginal people face unique health challenges 2Health News:New type of stent could help some brain aneurysm patients 2Health News:Lung cancer study hints at new treatments 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:Study cracks how the brain processes emotions 2
... bleary- eyed Britons, relief from hay fever may soon ... designed to prevent// allergic reactions like a running nose, itching eyes, ... vaccine pill contains small amounts of Timothy grass pollen; main allergens ... before hay fever season. ,This pill follows the hay ...
... at Cornell University in Ithaca and Weill Cornell Medical ... of 23 protein biomarkers// in cerebrospinal fluid that acts ... to identify patients living with Alzheimer’s disease. ... of the journal Annals of Neurology. ,Right ...
... for under-14 is being conducted at the Auckland Aquatic Center ... participating in a game at the West Wave Aquatic Centre ... problems and had to be admitted in the hospital. ... The council is deeply concerned by what had occurred and ...
... by the Canadian Food Inspection Agency to the public asking them ... fear that it may be contaminated with salmonella. ,This ... 0 33383 65201 6 and Dec. 7. as the best before ... shops but the agency fears some people may still have it ...
... zonal hospital found themselves in peril after doctors and ... The resignation en masse was submitted on Sunday, citing ... doctors – said senior physician Dr Gaurang Mishra. ... Dr. Raj Kumar Mahoto were beaten up by the ...
... For smokers, it ‘s bad news again. The Queensland (Australia) ... ,Smoking will soon be prohibited in cars carrying ... finding that one child under five years of age, dies ... ,The Queensland Health Minister while unveiling the Health of Queenslanders ...
Cached Medicine News:Health News:Revolutionary Pill Promises Relief for Hay Fever Sufferers 2Health News:Protein ‘Fingerprint’ in Spinal Fluid Could Spot Alzheimer’s Dise 2Health News:Protein ‘Fingerprint’ in Spinal Fluid Could Spot Alzheimer’s Dise 3
... The Sysmex pocH-100i is the first Sysmex ... low daily testing requirements. With its small ... differential from just 15 L of whole ... any small healthcare site including the emergency ...
... a self-contained, compact, easy-to-use, bedside automated cell ... Ichor system provides a hematology profile of ... platelet aggregation within five minutes. The test ... is added to both an EDTA baseline ...
... pacemaker family, which includes the world's ... the most advanced pacemaker technology available, ... the first and only U.S. commercially ... fibrillation (AF). The AF Suppression algorithm ...
... catheters that are controlled by an ... console processes the refrigerant, which when ... the catheter, creates cryogenic temperatures., ,The ... touch-screen interface. From this interface, the ...
Medicine Products: